MAPMI Ultra-Broad-Spectrum Pathogen mNGS Test CapitalBio

Features

1. Detection of 16109 viruses, 13362 bacteria, 1659 fungi, 270 parasites, and 2500 drug resistance genes

2. 

3. Target population

• Patients who fall into this category have been identified as immunosuppressed hosts, patients with underlying disorders, and patients with severe infections who have been hospitalized multiple times.

• Patients who repeatedly fail standard microbiological tests and have suboptimal treatment responses.

• Patients who are clinically suspected of harboring emerging diseases and who show infectious signs.

• Individuals who may be infected with specific virus.

• Patients with additional clinical signs, prolonged fever, and/or infections of unknown etiology.

• The MAPMI Test is also available at CapitalBiotech Medical Lab.